Skip to main content Skip to footer
Algernon Pharmaceuticals Inc.
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Alzheimer’s
    • Overview
    • AD Clinics
    • Markets
    • Resources
  • Pipeline
    • Overview
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

News Releases

Jan 14, 2022 8:15am EST

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study

Jan 04, 2022 9:15am EST

Algernon Pharmaceuticals Issues Compensation Options

Dec 08, 2021 7:04am EST

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Dec 02, 2021 7:00am EST

Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial

Nov 30, 2021 7:00am EST

Algernon Pharmaceuticals Announces New Chief Financial Officer

Nov 24, 2021 7:00am EST

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study

Nov 23, 2021 4:01pm EST

Algernon Pharmaceuticals Announces Effective Date of Previously Announced Share Consolidation

Nov 19, 2021 7:00am EST

Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study

Nov 17, 2021 4:14pm EST

Algernon Pharmaceuticals Announces Share Consolidation

Nov 01, 2021 7:00am EDT

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • …
  • …Page 22
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
©2025 Algernon Pharmaceuticals Inc. All Rights Reserved.
Privacy Policy Sitemap